The Manufacturer-Pays Model for Planning
How the manufacturer pays surgical planning model works: surgeons plan free, the OEM pays because the plan supports correct sizing and use of its implant.
Key takeaways
The manufacturer-pays surgical planning model inverts who writes the check. Instead of asking a surgeon to buy a planning subscription, the software is free at the point of use and the implant manufacturer pays for it, because a good pre-operative plan supports correct sizing, alignment, and confident use of that manufacturer's implant. This only works cleanly when the planner is implant-agnostic and vendor-neutral: the plan follows the anatomy first, then fits the chosen implant library, so the manufacturer funds a workflow rather than being sold one. For an OEM without its own robot or planning platform, this is a way to offer modern digital planning that travels with its catalog. Deal shapes range from per-plan pricing to an annual floor, a white-label license, or co-development with IP defined by contract. Salnus builds exactly this kind of software for manufacturers to license, currently Research Use Only (RUO), so engagements start as pilots and co-development, not as a purchase of a cleared product.
Why the money follows the value
Follow the value and you find who should pay. A pre-operative plan does not exist for its own sake: it exists so a specific implant goes in at the right size, in the right position, with fewer surprises in theater. The party that captures value from correct implant selection and use is the manufacturer, not the surgeon writing a software invoice. When the surgeon is asked to pay for planning, adoption stalls on budget cycles and per-seat friction. When the manufacturer pays, planning becomes part of how it supports its own product, and the surgeon simply gets a better tool at no direct cost.
This is why the manufacturer-pays model and vendor-neutral planning belong together. If planning is bundled inside one robot or one brand's ecosystem, it is really a sales funnel, and its neutrality is gone. An implant-agnostic, vendor-neutral planner keeps the anatomy work independent of the implant, then applies the selected component library at the end. That neutrality is what lets several manufacturers each fund the same underlying engine for their own catalog without the tool secretly steering toward a competitor.
What the manufacturer actually funds
An OEM paying for planning is not buying pixels. It is funding a workflow that touches its commercial reality at several points:
- Sizing support. A CT-based 3D plan that estimates component size before the case can reduce tray uncertainty and support more predictable inventory conversations.
- Alignment context. Neutral presentation of alignment options and phenotype lets the surgeon plan on the anatomy, with the manufacturer's implant fitted to that plan rather than the reverse.
- A modern digital front door. Manufacturers without a robot or an in-house planner still want to be present where surgeons plan. Licensed vendor-neutral software gives them that presence.
- Differentiation without hardware. Not every manufacturer will build a capital-heavy robot. Software that works with its existing catalog is a lighter path to a digital offering, and the trade-offs against a full robotic system are worth understanding.
None of this is a clinical-outcomes claim. Salnus software is RUO and not a cleared device, so the honest framing is workflow and evidence-building, not proven surgical superiority.
The deal shapes
There is no single contract. The manufacturer-pays model expresses itself in a few recurring structures, and the right one depends on volume, exclusivity appetite, and how much of the brand the manufacturer wants on the interface. We do not quote prices here: the point is the shape, not the number.
Per-plan. The manufacturer pays for each plan generated on its implant library. This aligns cost directly with usage and is easy to reason about when volumes are uncertain. It suits a manufacturer testing whether digital planning moves anything before committing to a fixed spend.
Annual floor. A committed yearly minimum, often with per-plan pricing above the floor. This gives both sides predictability: the manufacturer secures capacity and priority, and the software partner can plan a roadmap against a known baseline. It fits a manufacturer that already believes in the workflow and wants budget certainty.
White-label license. The manufacturer presents the planning experience under its own brand, licensing the underlying vendor-neutral engine. Useful when the OEM wants the surgeon relationship to feel native to its ecosystem. The neutrality still lives in the engine, but the surface carries the manufacturer's identity, and the license terms define what is exclusive and what is not.
Co-development with IP retained. The manufacturer co-funds specific extensions, a new anatomy, a catalog integration, a particular sizing behavior, while the core planning IP stays with the software builder. This is the structure for a manufacturer that wants something tailored without acquiring or forking the platform. The contract, not the funding source, decides ownership: co-funding an extension does not silently transfer the core.
Across all four, the governing principle is that IP is contract-defined. A manufacturer can fund a great deal of surrounding work and still not own the core planning engine, and that clarity up front is what keeps a vendor-neutral platform genuinely neutral for the next manufacturer that licenses it.
Where this sits in a manufacturer's options
A product or BD leader comparing digital planning options is really choosing among build, buy a robot, or license neutral software. Building in-house is slow and pulls a device company into a machine-learning discipline it may not want to own. A capital robot is a different business entirely, with its own sales motion and lock-in. Licensing a vendor-neutral planner under a manufacturer-pays deal is the lightest path to a credible digital offering, and it is worth seeing how the current landscape of AI knee-planning offerings and the broader 3D planning software compared for 2026 actually break down before committing.
The honest caveat holds throughout. Salnus is Research Use Only. A manufacturer engagement is a pilot and a co-development relationship with evidence gathered along the way, not a turnkey purchase of a cleared product. That is the correct starting posture for any serious medtech decision-maker, and it is how we frame every conversation.
Bottom line
The manufacturer-pays model works because it puts the cost where the value is: the surgeon plans free, and the manufacturer pays because a sound, vendor-neutral plan supports correct sizing and confident use of its implant. The deal can be per-plan, an annual floor, a white-label license, or co-development with IP retained, and in every case the contract defines ownership so the platform stays neutral for everyone who licenses it. If you are deciding how your company offers modern digital planning, see how Salnus works with manufacturers to scope a pilot.
Reviewed by the Salnus biomedical engineering team.